CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

idecabtagene vicleucel

Last Updated: December 17, 2020
Result type: Reports
Project Number: PG0240-000
Product Line: Reimbursement Review

Generic Name: idecabtagene vicleucel

Brand Name: TBC

Manufacturer: Celgene Inc., a Bristol Myers Squibb company

Therapeutic Area: Multiple myeloma

Indications: For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Submission Type: Initial

Tumour Type: Myeloma

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Schedule E

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 18, 2020
Call for patient/clinician input closedJanuary 15, 2021
Clarification:

- Patient input submission received from Myeloma Canada

Submission receivedDecember 16, 2020
Submission acceptedJanuary 07, 2021
Review initiatedJanuary 08, 2021
Draft CADTH review report(s) provided to sponsor for commentMarch 26, 2021
Deadline for sponsors commentsApril 07, 2021
CADTH responses on draft review report(s) provided to sponsorMay 03, 2021
Expert committee meeting (initial)May 13, 2021
Draft recommendation issued to sponsorMay 26, 2021
To
May 28, 2021
Draft recommendation posted for stakeholder feedback-